摘要
瞄准：与 infusional 评估 bevacizumab 的联合 5 氟尿嘧啶(5-FU ) ，甲酰四氢叶酸(LV ) 和在有先进颜色的病人的 irinotecan (FOLFIRI ) 有包括 irinotecan 和 oxaliplatin 的联合政体的表面的癌症(CRC ) pretreated。方法：十四个病人(中部的年龄 56 年) 与先进 CRC，都在基于 oxaliplatin 、基于 irinotecan 的联合化疗以后进行了，在这研究被注册。病人们与 irinotecan 的 2 h 注入被对待 d 上的 150 mg/m2 1 ，正 bevacizumab 为 d 上的 90 min 的 5 mg/kg iv 注入 2 ，并且 LV 20 mg/m2 的 iv 注射由 5-FU 的一丸大丸药跟随了 400 mg/m2 然后 22 h 在二连续的天给每 14 d 的 600 mg/m2 的连续注入。结果：化疗的周期的中部的数字是六(范围 3-12 ) 。反应率是 28.5% ，一个病人有完全的回答，并且三个病人有部分回答。八个病人有稳定的疾病。前进的中部的时间是 3.9 瞬间(95% CI 2.0-8.7 ) ，并且中部的全面幸存是 10.9 瞬间(95% CI 9.6-12.1 ) 。等级 3/4 嗜中性白血球减少症在五个病人发生了，并且这些中的二个得了 neutropenic 发烧。等级 3 血尿症和便血发生在一个。等级 2 蛋白尿发生在二个病人。然而，高血压，肠穿孔或 thromboembolic 事件没总共 90 个周期的发生。结论：有 FOLFIRI 的 Bevacizumab 很好被容忍并且在有重重地对待的先进 CRC 的病人的可行治疗。
AIM： To evaluate the combination of bevacizumab with infusional 5-fluorouracil （5-FU）, leucovorin （LV） and irinotecan （FOLFIRI） in patients with advanced colorectal cancer （CRC） pretreated with combination regimens including irinotecan and oxaliplatin. METHODS： Fourteen patients （median age 56 years） with advanced CRC, all having progressed after oxaliplatin- and irinotecan-based combination chemotherapy, were enrolled in this study. Patients were treated with 2 h infusion of irinotecan 150 mg/m2 on d 1, plus bevacizumab 5 mg/kg iv infusion for 90 min on d 2, and iv injection of LV 20 mg/m2 followed by a bolus of 5-FU 400 mg/m2 and then 22 h continuous infusion of 600 mg/m2 given on two consecutive days every 14 d. RESULTS： The median number of cycles of chemotherapy was six （range 3-12）. The response rate was 28.5%, one patient had a complete response, and three patients had a partial response. Eight patients had stable disease. The median time to progression was 3.9 mo （95% CI 2.0-8.7）, and the median overall survival was 10.9 mo （95% CI 9.6-12.1）. Grade 3/4 neutropenia occurred in five patients, and two of these developed neutropenic fever. Grade 3 hematuria and hematochezia occurred in one. Grade 2 proteinuria occurred in two patients. However, hypertension, bowel perforation or thromboembolic events did not occur in a total of 90 cycles. CONCLUSION： Bevacizumab with FOLFIRI is well tolerated and a feasible treatment in patients with heavily treated advanced CRC.
